Paul Rodriguez, MD

home / authors / paul-rodriguez-md

Articles

Complete Pathologic Response to Neoadjuvant Chemoimmunotherapy and Oxaliplatin-Induced Fever Associated With IL-6 Release in a Patient With Locally Advanced Colon Cancer

Mehmet Sitki Copur, MD, FACP;Caleb W. Schroeder, MD;Quan Ly, MD;Whitney Wedel, MD;Jacqueline R. Kelly, MD, MSc;Paul Rodriguez, MD;Soe Min Tun, MD, MBA, MSc;Nicholas Lintel, MD;Adam J. Horn, MD;Bronson Riley, CGC

February 15th 2022

This case presents a patient with locally advanced, unresectable, mismatch repair–deficient sigmoid colon cancer who was treated with neoadjuvant chemoimmunotherapy followed by surgical resection leading to a complete pathologic response after preoperative systemic chemoimmunotherapy.

A 65-Year-Old Man With Back Pain and Imaging Findings of Spinal Cord Compression

Mehmet Sitki Copur, MD;Scott Bell, MD, PhD, MPH;Paul Rodriguez, MD;Whitney Wedel, MD;Nicholas Lintel, MD;Thomas Zusag, MD;John L. Allen, MD

March 18th 2021

Mehmet S. Copur, MD, and colleagues examine the case of a 65-year-old who presented with back pain and a large T8 spinal mass, leading to a diagnosis of multiple myeloma with spinal cord compromise.

Recurrent EGFR-Mutated Non–Small Cell Lung Cancer Discovered by Abnormal Mammogram: Adjuvant/Frontline Metastatic Management Options

Mehmet Sitki Copur, MD;Rudy P. Lackner, MD;Adam J. Horn, MD;Thomas Zusag, MD;Shellie Faris, MD;Paul Rodriguez, MD

September 21st 2020

ABSTRACT: Breast metastasis from extramammary malignancy is rare, with a reported incidence rate of 0.4% to 1.3% in the published literature. The primary malignancies that most commonly metastasize to the breast are leukemia, lymphoma, and malignant melanoma. Here, we report a very rare case of metastatic EGFR-mutated non–small cell lung cancer (NSCLC) in the breast detected by screening mammography. The patient had initially been diagnosed with a clinical stage IIIA NSCLC and had been treated with neoadjuvant chemoradiation followed by curative-intent surgery. Several interesting aspects of the case, along with a discussion of evolving adjuvant and frontline metastatic management options in EGFR-mutated NSCLC, will be presented.